Ethyl Acetate

Ethyl Acetate

SCHEMBL3246104

CCOC(C)=O.Cc1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Ethyl Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
LMNA P02545 8/20 0.50
KMT2A Q03164 4/20 0.50
HSD17B10 Q99714 2/20 0.50
GAA P10253 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
RECQL P46063 1/20 0.47
KDM4E B2RXH2 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TSHR P16473 1/20 0.46
MAPT P10636 2/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP2D6 P10635 1/20 0.43
POLB P06746 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL27528963 0.86 KMT2A (0.40) ALDH1A1LMNAKMT2AHSD17B10GAA
Ethyl Acetate SCHEMBL4278294 0.86 TSHR (0.57) ALDH1A1LMNAKMT2AHSD17B10GAA
P-Xylene SCHEMBL2536913 0.84 ALDH1A1 (0.70) ALDH1A1LMNAKMT2AHSD17B10GAA
Ethyl Propionate SCHEMBL28248668 0.84 CYP1A2 (0.51) ALDH1A1LMNAKMT2AHSD17B10GAA
Acetic Acid Methyl Ester SCHEMBL28854245 0.83 MEN1 (0.51) ALDH1A1LMNAKMT2AGAACYP1A2
Ether SCHEMBL1964593 0.83 ALDH1A1 (0.47) ALDH1A1LMNAKMT2AHSD17B10GAA
SCHEMBL5178584 0.83 LMNA (0.47) ALDH1A1LMNAKMT2AGAACYP1A2
Acetone SCHEMBL4283217 0.82 GAA (0.54) ALDH1A1LMNAGAACYP1A2CYP2C9
Propane SCHEMBL28408609 0.82 GAA (0.54) ALDH1A1LMNAKMT2AGAACYP1A2
Propane SCHEMBL3563886 0.82 GAA (0.54) ALDH1A1LMNAKMT2AGAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117164481-A Methyl (3-methylaminopropyl) carbamate derivatives of ZL006-05 and pharmaceutically acceptable salts thereof and pharmaceutical application thereof 苏州南医大创新中心 2023-12-05 CN disclosed
WO-2023095785-A1 PHOTOSENSITIVE RESIN COMPOSITION, CURED ARTICLE, ORGANIC EL DISPLAY DEVICE, SEMICONDUCTOR DEVICE, AND METHOD FOR PRODUCING CURED ARTICLE 東レ株式会社 2023-06-01 WO disclosed
CN-103965194-B Triazole antifungal compound, its pharmaceutical composition and its production and use 中国科学院上海药物研究所 2016-08-17 CN disclosed
EP-1369418-B1 QUINAZOLINE DERIVATIVES MITSUBISHI TANABE PHARMA CORP (JP) 2010-07-28 EP disclosed
US-20090137580-A1 Fused Heterocyclic Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US disclosed
EP-1904498-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-04-02 EP disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 US disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
WO-2007004749-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 WO disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-20040116422-A1 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2004-06-17 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
EP-1369418-A1 QUINAZOLINE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2003-12-10 EP disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed
US-4071550-A Process for the production of aminocyanoacetic acid ethyl ester LONZA, LTD. (CH) 1978-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A ALDH1A1 443/4885LMNA 3559/4885KMT2A 765/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A ALDH1A1 443/4885LMNA 3559/4885KMT2A 765/4885
US-20090137580-A1 Fused Heterocyclic Derivatives and Use Thereof TIE1, KDR, FLT1 ALDH1A1 2646/4885LMNA 4763/4885KMT2A 219/4885
US-20070265260-A1 Quinazoline derivatives TYK2, ROR1, JAK1 ALDH1A1 3381/4885LMNA 2908/4885KMT2A 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.